Ad
GRTS Stock - Gritstone Oncology Stock Trading
About | Gritstone Oncology Inc. (NASDAQ:GRTS)
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.
Quote | Gritstone Oncology Inc. (NASDAQ:GRTS)
| Last: | $0.5093 |
|---|---|
| Change Percent: | -1.17% |
| Open: | $0.4999 |
| Close: | $0.5093 |
| High: | $0.5179 |
| Low: | $0.4941 |
| Volume: | 429,896 |
| Last Trade Date Time: | 09/10/2024 03:00:00 am |
News | Gritstone Oncology Inc. (NASDAQ:GRTS)
-
2024-08-13 17:29:58 ET More on Gritstone bio Seeking Alpha’s Quant Rating on Gritstone bio Historical earnings data for Gritstone bio Financial information for Gritstone bio Read the full article on Seeking Alpha For further details see: Gr...
-
-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- ...
Message Board Posts | Gritstone Oncology Inc. (NASDAQ:GRTS)
| Subject | By | Source | When |
|---|---|---|---|
| AACR PR https://www.globenewswire.com/news-release/2023/04/17/2647754/0/en/Grits | jondoeuk | investorshub | 04/17/2023 8:03:02 PM |
| Nice...$$$$!!!???????? | Little Run | investorshub | 01/07/2023 12:19:22 AM |
| Nice...$$$$!!!???????? | Little Run | investorshub | 01/07/2023 12:19:21 AM |
| Holy Fuck...Still just me! | Little Run | investorshub | 12/21/2022 2:25:03 AM |
| znewcar1: $GRTS 26% v6,19M C3.92 f83,4M H4.05 ML2.49 | znewcar1 | investorshangout | 12/15/2022 12:55:46 AM |
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
Ad
-
-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- ...
-
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...
-
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
Important Investor News Alert (OTC: AABB)
-
LAS VEGAS, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that the Company has been thrilled with the rise in gold and silver prices this year and the corresponding increases to AABB’s quarterly...